MECHANISM OF ACTION
The Shredded Stack combines three complementary fat-reduction mechanisms: AOD-9604 directly stimulates β3-adrenergic lipolysis in adipocytes without IGF-1 elevation. MOTS-C activates AMPK to enhance fat oxidation, improve insulin sensitivity, and increase resting metabolic rate. Tesamorelin stimulates pulsatile GH to specifically target visceral adipose tissue (the FDA-approved mechanism). Together: direct fat cell breakdown (AOD) + enhanced metabolic efficiency (MOTS-C) + visceral fat GH signalling (Tesamorelin) - three mechanistically distinct pathways operating in parallel.
RESEARCH APPLICATIONS
- Multi-mechanism adipose tissue research protocol
- Visceral adiposity reduction (abdominal fat)
- Body recomposition research - lean mass preservation concurrent with adipose reduction
- Metabolic rate enhancement without stimulants
- Type 2 diabetes-adjacent metabolic research
RESEARCH HIGHLIGHTS
Complementary Fat Loss Mechanisms
AOD-9604 (lipolysis, no IGF-1 elevation), MOTS-C (AMPK/metabolic rate), Tesamorelin (visceral GH signal) provide three distinct, non-overlapping fat-reduction pathways.
Ref: See individual compound pages
RESEARCH PROTOCOL NOTES
Chemical Identity
Storage & Stability
2–8°C. Reconstituted blend follows most sensitive component (Tesamorelin: use within 3 hours if no preservative, or 21 days bacteriostatic).
Regulatory Status
Research compound blend. MOTS-C not WADA listed. Tesamorelin WADA S2 prohibited. AOD-9604 not explicitly listed on WADA prohibited list. SAHPRA: all components unscheduled.